In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure

Jacob Yahav; Haim Shmuely; Yaron Niv; Jacklin Bechor; Zmira Samra

doi:10.1016/j.diagmicrobio.2005.12.003

In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure

Jacob Yahav
, Haim Shmuely
, Yaron Niv
, Jacklin Bechor
, Zmira Samra

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

We tested the in vitro activity of levofloxacin (LEV), amoxicillin (AMP), clarithromycin (CLA), metronidazole (MET), and tetracycline (TET) against 70 clinical isolates of Helicobacter pylori recovered from 70 dyspeptic patients. All patients had previously failed 2 treatment regimens: first-line triple therapy with omeprazole, AMP, and CLA, and second-line quadruple therapy with omeprazole, MET, TET, and bismuth. Resistance to CLA, MET, and LEV was found in 65.7%, 57.1%, and 18.6% of isolates, respectively. Resistance to both CLA and MET was found in 32.8%, and to CLA, MET, and LEV in 12.8%. Only 4 of the isolates were resistant to both CLA and LEV, and none was resistant to LEV alone or to MET and LEV. Physicians should consider triple therapy with omeprazole, LEV, and AMP in patients unsuccessfully treated with first- and second-line regimens.

Original language	English
Pages (from-to)	81-83
Number of pages	3
Journal	Diagnostic Microbiology and Infectious Disease
Volume	55
Issue number	1
DOIs	https://doi.org/10.1016/j.diagmicrobio.2005.12.003
State	Published - May 2006
Externally published	Yes

Keywords

Helicobacter pylori
In vitro susceptibility, treatment
Levofloxacin

Access to Document

10.1016/j.diagmicrobio.2005.12.003

Cite this

@article{4b1b03fe770e4fc0b0f6a1d8c70a4956,

title = "In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure",

abstract = "We tested the in vitro activity of levofloxacin (LEV), amoxicillin (AMP), clarithromycin (CLA), metronidazole (MET), and tetracycline (TET) against 70 clinical isolates of Helicobacter pylori recovered from 70 dyspeptic patients. All patients had previously failed 2 treatment regimens: first-line triple therapy with omeprazole, AMP, and CLA, and second-line quadruple therapy with omeprazole, MET, TET, and bismuth. Resistance to CLA, MET, and LEV was found in 65.7\%, 57.1\%, and 18.6\% of isolates, respectively. Resistance to both CLA and MET was found in 32.8\%, and to CLA, MET, and LEV in 12.8\%. Only 4 of the isolates were resistant to both CLA and LEV, and none was resistant to LEV alone or to MET and LEV. Physicians should consider triple therapy with omeprazole, LEV, and AMP in patients unsuccessfully treated with first- and second-line regimens.",

keywords = "Helicobacter pylori, In vitro susceptibility, treatment, Levofloxacin",

author = "Jacob Yahav and Haim Shmuely and Yaron Niv and Jacklin Bechor and Zmira Samra",

year = "2006",

month = may,

doi = "10.1016/j.diagmicrobio.2005.12.003",

language = "אנגלית",

volume = "55",

pages = "81--83",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure

AU - Yahav, Jacob

AU - Shmuely, Haim

AU - Niv, Yaron

AU - Bechor, Jacklin

AU - Samra, Zmira

PY - 2006/5

Y1 - 2006/5

N2 - We tested the in vitro activity of levofloxacin (LEV), amoxicillin (AMP), clarithromycin (CLA), metronidazole (MET), and tetracycline (TET) against 70 clinical isolates of Helicobacter pylori recovered from 70 dyspeptic patients. All patients had previously failed 2 treatment regimens: first-line triple therapy with omeprazole, AMP, and CLA, and second-line quadruple therapy with omeprazole, MET, TET, and bismuth. Resistance to CLA, MET, and LEV was found in 65.7%, 57.1%, and 18.6% of isolates, respectively. Resistance to both CLA and MET was found in 32.8%, and to CLA, MET, and LEV in 12.8%. Only 4 of the isolates were resistant to both CLA and LEV, and none was resistant to LEV alone or to MET and LEV. Physicians should consider triple therapy with omeprazole, LEV, and AMP in patients unsuccessfully treated with first- and second-line regimens.

AB - We tested the in vitro activity of levofloxacin (LEV), amoxicillin (AMP), clarithromycin (CLA), metronidazole (MET), and tetracycline (TET) against 70 clinical isolates of Helicobacter pylori recovered from 70 dyspeptic patients. All patients had previously failed 2 treatment regimens: first-line triple therapy with omeprazole, AMP, and CLA, and second-line quadruple therapy with omeprazole, MET, TET, and bismuth. Resistance to CLA, MET, and LEV was found in 65.7%, 57.1%, and 18.6% of isolates, respectively. Resistance to both CLA and MET was found in 32.8%, and to CLA, MET, and LEV in 12.8%. Only 4 of the isolates were resistant to both CLA and LEV, and none was resistant to LEV alone or to MET and LEV. Physicians should consider triple therapy with omeprazole, LEV, and AMP in patients unsuccessfully treated with first- and second-line regimens.

KW - Helicobacter pylori

KW - In vitro susceptibility, treatment

KW - Levofloxacin

UR - https://www.scopus.com/pages/publications/33646469364

U2 - 10.1016/j.diagmicrobio.2005.12.003

DO - 10.1016/j.diagmicrobio.2005.12.003

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16490341

AN - SCOPUS:33646469364

SN - 0732-8893

VL - 55

SP - 81

EP - 83

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 1

ER -

In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this